DEXFENFLURAMINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC POTENTIAL IN OBESITY

被引:115
作者
MCTAVISH, D
HEEL, RC
机构
[1] Adis International Limited, Auckland, 41 Centorian Drive, Private Bag 65901, Mairangi Bay
关键词
D O I
10.2165/00003495-199243050-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dexfenfluramine stimulates serotoninergic activity by inhibiting serotonin reuptake into presynaptic neurons and by enhancing its release into brain synapses. Based on the serotonin hypothesis of appetite control these effects would be expected to reduce food intake and thus bodyweight. Studies in animal models and severely overweight patients have confirmed the effectiveness of dexfenfluramine as a weight-reducing agent which appears to be well tolerated. Permanent weight loss is the goal of weight-reducing strategies and, based on current clinical evidence, dexfenfluramine appears to exert a weight reducing effect over periods of up to 12 months without development of tolerance, a problem that has limited the long term use of other pharmacological agents used in the treatment of this disorder. Dexfenfluramine facilitated weight loss in patients who had not responded satisfactorily to other weight-reducing strategies, prevented relapse in those patients who had achieved weight reduction by other methods, and corrected disturbed eating patterns (and therefore reduced weight gain) in small studies involving patients with premenstrual syndrome, seasonal affective disorder and nicotine withdrawal syndrome. Follow-up of the longest study reported with dexfenfluramine suggests that continued therapy is required in severely overweight patients if weight loss is to be maintained. Dexfenfluramine has not been directly compared with nonpharmacological measures of weight control such as behaviour modification or exercise programmes. The decision that pharmacological means are indicated in overweight patients must be highly individualised, and must consider the many complex factors that often contribute to overweight states, as well as the anticipated magnitude of drug effect. Despite such a cautionary note, and the expected need (at this stage of its development) for an expanded clinical study programme in certain areas, dexfenfluramine is a clear advance in the pharmacological approach to improved management of overweight individuals.
引用
收藏
页码:713 / 733
页数:21
相关论文
共 87 条
[11]   OVERWEIGHT IS RISKING FATE - DEFINITION, CLASSIFICATION, PREVALENCE, AND RISKS [J].
BRAY, GA .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1987, 499 :14-28
[12]  
BRZEZINSKI AA, 1990, OBSTET GYNECOL, V76, P296
[13]  
CABALLERO B, 1987, INT J OBESITY, V11, P179
[14]   PHARMACOKINETICS OF FENFLURAMINE AND NORFENFLURAMINE IN VOLUNTEERS GIVEN D-FENFLURAMINE AND DL-FENFLURAMINE FOR 15 DAYS [J].
CACCIA, S ;
CONFORTI, I ;
DUCHIER, J ;
GARATTINI, S .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 29 (02) :221-224
[15]  
CACCIA S, 1982, ARCH INT PHARMACOD T, V258, P15
[16]  
CARLTON J, 1989, INT J OBESITY, V13, P825
[17]   DOPAMINERGIC AND SEROTONINERGIC ANORECTICS DIFFERENTIALLY ANTAGONIZE INSULIN-INDUCED AND 2-DG-INDUCED HYPERPHAGIA [J].
CARRUBA, MO ;
RICCIARDI, S ;
SPANO, PF ;
MANTEGAZZA, P .
LIFE SCIENCES, 1985, 36 (18) :1739-1749
[18]   MANAGEMENT STRATEGIES FOR WEIGHT CONTROL EATING, EXERCISE AND BEHAVIOR [J].
CATERSON, ID .
DRUGS, 1990, 39 :20-32
[19]  
Clineschmidt B V, 1978, Ann N Y Acad Sci, V305, P222, DOI 10.1111/j.1749-6632.1978.tb31526.x
[20]  
DAMSBO P, 1991, DIABETES S1, V40, pA307